Thomas A.Briggs (Tom)

Partner

San Diego + 1.858.314.1164

Tom Briggs negotiates technology-based transactions, such as licenses, strategic alliances, joint ventures, mergers, acquisitions, and divestitures, where information, knowledge, and intellectual property constitute key subject matter. Tom also negotiates agreements that involve the transfer, protection, or sharing of IP or of new products and services, such as for distribution, manufacturing, supply, software and services, joint development, sponsored research, clinical trials, employee IP rights, and consulting. Tom is a founder and former co-leader of Jones Day's IP Licensing and Technology Transactions team.

Tom has deep experience representing clients in cross-border transactions, in particular between the USA, Japan, China, and Europe. Clients include Athersys, Bunge, Celgene, EagleTree Capital, Genomatica, Idemitsu Kosan, Incyte, Ishihara Sangyo Kaisha, Koch, Micreos, P&G, Shanghai Junshi, and Toolgen.

Tom leverages his engineering career and scientific training by focusing on transactions that involve pharmaceuticals, biotech, medical devices, food, agriculture, semiconductors, software, polymers, fermentation, industrial chemicals, steel, oil, gas, and big data. He also regularly gives educational seminars on various intellectual property and transaction subjects in public and private settings.

In helping clients with their technology transactions, Tom draws upon a rare combination of work experiences. He is a patent lawyer who has litigated cases involving infringement, misappropriation, and noncompetition and has prosecuted patent and trademark registrations. He has served as chief intellectual property officer and assistant general counsel of M.A. Hanna Company (now PolyOne Corporation). He also spent 10 years as a practicing chemical engineer and plant supervisor with Union Carbide/Praxair before his career as a lawyer.

Experience

  • Cooper Tire & Rubber sold to The Goodyear Tire & Rubber Company for approximately $2.5 billion enterprise valueJones Day advised Cooper Tire & Rubber Company in its $2.5 billion sale to The Goodyear Tire & Rubber Company.
  • Xact Data Discovery sells company to Aquiline Capital PartnersJones Day represented Xact Data Discovery, a leading international provider of eDiscovery, data management, and managed review services for major law firms and corporations and portfolio company of JLL Partners, in connection with its acquisition by Aquiline Capital Partners LLC, a New York-based private equity firm.
  • Junshi Biosciences collaborates with Coherus Biosciences to co-develop anti-PD-1 antibody and grants options for anti-TIGIT and IL-2 cytokine moleculesJones Day represented Junshi Biosciences in its license out of technology and IP related to an anti-PD-1 antibody known as Toripalimab and options for two other molecules.
  • Micreos teams up with L'Oréal for skin care products containing endolysinsJones Day represented Micreos Human Health B.V. in its license out to L'Oréal of endolysin technology that targets harmful skin bacteria while preserving useful bacteria for L'Oréal's use worldwide in skin care products for cosmetic applications.
  • Furukawa Electric and Superior Essex global joint venture finalizedJones Day advised Furukawa Electric Co., Ltd. in its finalization of a global joint venture with Superior Essex Inc.
  • Polaris teams up with Zero Motorcycles to electrify ATVs and snowmobilesJones Day represented Polaris Industries Inc., OEM of off-road vehicles/ATVs, snowmobiles, motorcycles and boats sold under the POLARIS, RZR, RANGER, GENERAL, SPORTSMAN, INDIAN, and HURRICANE brands, among others, on its entry into a joint development, licensing, and services relationship with Zero Motorcycles, a global leader in electronic motorcycle powertrains and technology.
  • Junshi and Revitope team up for TEAC molecules through development, license, and equityJones Day represented Shanghai Junshi Biosciences Co., Ltd. in a research collaboration and license agreement with Revitope Oncology Inc. and its subsidiary to collaborate in the research and development of T-cell engaging cancer immunotherapies that utilize Junshi's antibody technology platform with Revitope's proprietary dual-antigen targeting technology platform.
  • Junshi and Lilly to develop and commercialize antibodies for prevention and treatment of COVID-19 coronavirusJones Day represented Shanghai Junshi Biosciences Co., Ltd. in its strategic collaboration and license agreement with Eli Lilly and Company for the development, manufacturing, and commercialization of two antibodies for the prevention and treatment of the COVID-19 SARS-CoV-2 novel coronavirus.
  • Athersys completes $57.6 million public offering of Common StockJones Day represented Athersys, Inc., a clinical-stage biotechnology company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life, in connection with the $57.6 million underwritten public offering of 25,587,500 shares of Common Stock.
  • PGT Innovations acquires NewSouth Window SolutionsJones Day advised PGT Innovations, Inc., a national leader in premium windows and doors, including impact-resistant products, in connection with its $92 million cash acquisition of NewSouth Window Solutions, subject to adjustments.
  • VersaPeutics collaborates with UCSD in developing pharmaceutical candidates for treatment of neurological and oncological diseasesJones Day represented VersaPeutics, Inc. in its strategic collaboration and license agreement with University of California San Diego ("UCSD") for the development of pre-clinical stage therapeutic candidates for the treatment of certain neurological and oncological diseases.
  • Airtech acquires Champion Valves Inc. and Valve & Pump Specialties, Inc.Jones Day advised Airtech Group, a portfolio company of EagleTree Capital, in connection with the acquisition and related financing of Champion Valves Inc. and Valve & Pump Specialties, Inc., a designer, assembler, and distributor of industrial check valves and butterfly valves.
  • Incyte grants license to and collaborates with Zai Lab to develop and commercialize anti-PD1 pharmaceutical products in ChinaJones Day represented Incyte Corporation in its sublicense out to Zai Lab Limited of certain intellectual property rights to an anti-PD1 molecule licensed to Incyte from MacroGenics, Inc. globally in 2017 and which Incyte is actively developing in the U.S. and other jurisdictions outside of China.
  • AbbVie acquires MavupharmaJones Day advised AbbVie Inc. in its acquisition of Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer.
  • Genomatica enters sponsored research agreement relating to biofuels, acquires technology from REGIJones Day represented Genomatica, Inc. in entering a sponsored research agreement for the development of advanced biofuels and acted as special IP counsel to Genomatica in its simultaneous acquisition of the assets of the life sciences division of Renewable Energy Group, Inc. ("REGI").
  • Incyte enters strategic collaboration agreement with Innovent for three clinical pharmaceuticals in ChinaJones Day represented Incyte Pharmaceuticals in its strategic collaboration and license agreement with Innovent Biologics for the regulatory development and commercialization in China of three clinical stage pharmaceutical candidates, a FGFR1/2/3 inhibitor, a JAK1 inhibitor, and a PI3K delta inhibitor, for treatment of hematological and oncological diseases.
  • Procter & Gamble acquires consumer health business of Merck KGaAJones Day advised The Procter & Gamble Company (“P&G”) in its €3.375 billion ($4.2 billion) acquisition of the worldwide consumer health business of Merck KGaA.
  • Sanofi and Denali Therapeutics collaborate to develop treatments for neurological and inflammatory diseasesJones Day represented Sanofi in its strategic collaboration and license agreement with Denali Therapeutics for the development, manufacturing, and commercialization of many pre-clinical and clinical candidates for treatment of certain neurological and systemic inflammatory diseases, including those known to target RIPK1, such as MS, Alzheimer's Disease and ALS, and rheumatoid arthritis.
  • EagleTree Capital acquires majority interest of Gaylord Chemical Company, LLCJones Day advised EagleTree Capital in its acquisition of a majority interest in and related financing of Gaylord Chemical Company, LLC, a specialty chemical producer.
  • EagleTree Capital acquires majority stake in FuseFXJones Day advised EagleTree Capital in connection with the acquisition of a majority stake in and related financing of FuseFX, LLC, a visual effects studio providing visual effects services for episodic television, feature films, commercials, and VR productions.
  • Speaking Engagements

    • November 7, 2018
      Licensing Fundamentals for Business Executives and Startups
    • May 6, 2015
      Licensing Fundamentals - for Business Executives and Startups, CONNECT Frameworks Workshop
    • May 7, 2014
      Licensing Fundamentals - for Business Executives and Startups, CONNECT Frameworks Workshop
    • November 6, 2013
      Technology Transfer: Adapting Models for BioInspired Success given at the San Diego Zoo's 4th Annual BioInspiration Conference
    • February 7, 2013
      Licensing Fundamentals for Business Executives and Startups, a CONNECT Frameworks Workshop
    • February 2, 2012
      Licensing Fundamentals for Business Executives and Startups
    • January 19, 2011
      Licensing Fundamentals for Business Executives and Startups
    • December 14, 2010
      Partnering Transactions for IP Development and Commercialization
    • August 12, 2010
      Licensing for Business Development Executives and Non-Licensing Attorneys
    • June 3, 2010
      Licensing Essentials Business Executives and Startups in the Life Sciences and Software Industries, a CONNECT Frameworks Workshop
    • January 20, 2010
      Licensing Essentials for Business Executives and Startups
    • January 14, 2010
      Transactions for Exploiting IP: Strategic Alternatives to M&A, Jones Day University
    • October 20, 2009
      Contentious IP Provisions in M&A and Licensing Transactions and Related Trends, CLE presentation
    • August 12, 2009
      Patents 101, Licensing and Exhaustion, CLE presentation
    • August 6, 2009
      The Latest on Current Big Ticket IP Issues: Obviousness and Patent Licensing/Exhaustion, ACCA San Diego Chapter, CLE presentation
    • June 10, 2009
      Fundamentals of Licensing Transactions - for Business Executives and Startups, CONNECT Frameworks Seminar
    • December 9, 2008
      Licensing Transactions in Life Sciences and Software for Business Executives, CONNECT Frameworks Seminar
    • February 5, 2008
      Fundamentals of Licensing in the Life Sciences, CONNECT Frameworks Seminar
    • February 15, 2007
      Fundamentals of Licensing in the Life Sciences, CONNECT Frameworks Seminar
    • December 11, 2006
      Advanced IP Support of M&A and Private Equity Transactions, CLE presentation
    • June 26, 2006
      Patents and Trade Secrets in the Food Industry, Annual Meeting of the Institute of Food Technologists
    • June 22, 2006
      World Class IP Practices: Management, Prosecution and Enforcement, CLE presentation
    • July 22, 2004
      Patents, Trade Secrets and Trademarks, CLE Presentation
    • February 25, 2004
      IP Licensing: Tips for the Taiwanese Semiconductor Industry, Taiwan Semiconductor Industry Association at the Industrial Technology Research Institute in the Science and Industrial Park
    • September 30, 2003
      IP Licensing: Tips for the Taiwan Semiconductor Industry, Taiwan Semiconductor Industry Association and ITRI
    • May 16, 2003
      Strategic Alternatives to Acquisitions, The 2003 Institute for Business Lawyers and Corporate Counsel
    • October 1, 2002
      IP and Technology Management, Taiwan Semiconductor Industry Association and National Taiwan University College of Law
    • November 12, 2001
      Learning from the Mistakes of the 90's, Tips on Licensing To and From Financially Troubled Companies